Last reviewed · How we verify
Darunavir, Ritonavir and Rilpivirine
This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps.
This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.
At a glance
| Generic name | Darunavir, Ritonavir and Rilpivirine |
|---|---|
| Sponsor | St Stephens Aids Trust |
| Drug class | Antiretroviral combination (protease inhibitor + NNRTI) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Darunavir and ritonavir are protease inhibitors that prevent HIV protease from cleaving viral polyproteins, blocking maturation of infectious viral particles. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the enzyme responsible for converting HIV RNA into DNA. Together, these three agents provide complementary antiretroviral activity against HIV-1.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
Common side effects
- Diarrhea
- Nausea
- Headache
- Rash
- Elevated liver enzymes
- Lipid abnormalities
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Population Pharmacokinetics of Antiretroviral in Children
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (PHASE4)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |